LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group Thierry Conrozier 1 , Raghu Raman 2 , Xavier Chevalier 3 , Yves Henrotin 4 , Jordi Monfort 5 , Demirhan Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Abstract Objectives: Hyaluronic acid viscosupplementation is a commonly used intra-articular treatment for osteoarthritis (OA). Some recent preclinical and clinical trials have demonstrated a potential for its disease-modifying effects. The goal of this expert Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Abstract Objectives The 3 aims of the work were to identify population subgroups that can benefit the most from viscosupplementation (VS), to provide recommendations on injection techniques, and to discuss VS appropriateness Read more…
Abstract Objectives: To assess, in daily practice conditions, both safety and efficacy of a single intra-articular injection of a cross-linked hyaluronic acid (HA) combined with mannitol (HANOX-M-XL) in patients with symptomatic knee osteoarthritis. Methods: We analyzed the clinical and radiological data of 53 consecutive patients with symptomatic knee OA, treated Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Abstract Rationale Viscosupplementation (VS) with hyaluronic acid is widely used in the management of knee osteoarthritis. There is no clear recommendation on the decision-making to achieve VS. Design Based on extensive research Read more…